RhumbLine Advisers’s VYNE Therapeutics VYNE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-2,696
| Closed | -$332K | – | 3111 |
|
|
2021
Q1 | $332K | Buy |
2,696
+181
| +7% | +$22.3K | ﹤0.01% | 2668 |
|
|
2020
Q4 | $286K | Buy |
2,515
+483
| +24% | +$54.9K | ﹤0.01% | 2689 |
|
|
2020
Q3 | $243K | Buy |
2,032
+38
| +2% | +$4.54K | ﹤0.01% | 2611 |
|
|
2020
Q2 | $248K | Buy |
1,994
+1,329
| +200% | +$165K | ﹤0.01% | 2668 |
|
|
2020
Q1 | $128K | Buy |
665
+380
| +133% | +$73.1K | ﹤0.01% | 2722 |
|
|
2019
Q4 | $95K | Buy |
285
+4
| +1% | +$1.33K | ﹤0.01% | 2876 |
|
|
2019
Q3 | $91K | Buy |
281
+27
| +11% | +$8.74K | ﹤0.01% | 2901 |
|
|
2019
Q2 | $109K | Buy |
254
+84
| +49% | +$36K | ﹤0.01% | 2917 |
|
|
2019
Q1 | $96K | Buy |
170
+9
| +6% | +$5.08K | ﹤0.01% | 2864 |
|
|
2018
Q4 | $48K | Buy |
+161
| New | +$48K | ﹤0.01% | 2946 |
|